Multiparametric (mp) prostate magnetic resonance imaging (MRI) is playing an increasingly prominent role in the diagnostic work-up of patients with suspected prostate cancer. Performing mpMRI before biopsy offers several advantages including biopsy avoidance under certain clinical circumstances and targeting biopsy of suspicious lesions to enable the correct diagnosis. The success of the technique is heavily dependent on high-quality image acquisition, interpretation, and report communication, all areas addressed by previous versions of the Prostate Imaging-Reporting and Data System (PI-RADS) recommendations. Numerous studies have validated the approach, but the widespread adoption of PI-RADS version 2 has also highlighted inconsistencies and limitations, particularly relating to interobserver variability for evaluation of the transition zone. These limitations are addressed in the recently released version 2.1. In this article, we highlight the key changes proposed in PI-RADS v2.1 and explore the background reasoning and evidence for the recommendations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.crad.2019.05.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deep Learning to Simulate Contrast-Enhanced MRI for Evaluating Suspected Prostate Cancer.
Radiology
January 2025
From the Department of Radiology, Shenzhen Nanshan People's Hospital, Shenzhen University, Taoyuan Rd No. 89, Nanshan District, Shenzhen 518000, Guangdong, China (H.H., Z.D., Y.Q.); Medical AI Laboratory and Guangdong Key Laboratory of Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, China (J.M., R.L., B.H.); Department of Medical Imaging, People's Hospital of Longhua, Shenzhen, Guangdong, China (X.P., Y.Z.); and Department of Radiology, Shenzhen People's Hospital, Shenzhen, Guangdong, China (D.Z., G.H.).
Background Multiparametric MRI, including contrast-enhanced sequences, is recommended for evaluating suspected prostate cancer, but concerns have been raised regarding potential contrast agent accumulation and toxicity. Purpose To evaluate the feasibility of generating simulated contrast-enhanced MRI from noncontrast MRI sequences using deep learning and to explore their potential value for assessing clinically significant prostate cancer using Prostate Imaging Reporting and Data System (PI-RADS) version 2.1.
View Article and Find Full Text PDFAutomatic Characterization of Prostate Suspect Lesions on T2-Weighted Image Acquisitions Using Texture Features and Machine-Learning Methods: A Pilot Study.
Diagnostics (Basel)
January 2025
Department of Medical Imaging, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
: Prostate cancer (PCa) is the most frequent neoplasia in the male population. According to the International Society of Urological Pathology (ISUP), PCa can be divided into two major groups, based on their prognosis and treatment options. Multiparametric magnetic resonance imaging (mpMRI) holds a central role in PCa assessment; however, it does not have a one-to-one correspondence with the histopathological grading of tumors.
View Article and Find Full Text PDFDiffuse, Bilateral Prostate Imaging Reporting and Data System (PI-RADS) 3 Changes Reported as Inflammation and Their Relation to Clinically Significant Prostate Cancer: A Retrospective Observational Study.
Cureus
December 2024
Urology, Northwick Park Hospital - London North West University Healthcare NHS Trust, Harrow, GBR.
Article Synopsis
- The study aimed to determine if diffuse, bilateral PI-RADS 3 changes on MRI of the prostate indicate clinically significant prostate cancer (csPCa).
- Data from 108 men with these MRI findings who underwent biopsies were analyzed, and it was found that 30.5% were diagnosed with csPCa.
- A significant correlation was identified between prostate-specific antigen density (PSAd) and the presence of cancer, suggesting that careful evaluation is needed before dismissing the need for biopsy in these cases.
Comparisons of three scoring systems based on biparametric magnetic resonance imaging for prediction of clinically significant prostate cancer.
Prostate Int
December 2024
Department of Medical Imaging, Jiangsu Vocational College of Medicine, Yancheng, China.
Purpose: In this study, we aimed to validate and compare three scoring systems based on biparametric magnetic resonance imaging (bpMRI) for the detection of clinically significant prostate cancer (csPCa) in biopsy-naïve patients.
Method: In this study, we included patients who underwent MRI examinations between January 2018 and December 2022, with MRI-targeted fusion biopsy (MRGB) as the reference standard. The MRI findings were categorized using three bpMRI-based scorings, in all of them the diffusion-weighted imaging (DWI) was the dominant sequence for peripheral zone (PZ) and T2-weighed imaging (T2WI) was the dominant sequence for transition zone (TZ).
Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?
World J Surg Oncol
December 2024
Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey.
Purpose: Although 18 F-FDG-PET/CT is helpful in defining many types of cancer, localized prostate cancer should not be treated with this technique. This study describes the use of multi-parametric MRI (mpMRI) to characterize incidental 18 F-FDG uptake in the prostate.
Methods And Materials: While 18 F-FDG-PET/CT is useful for characterizing a variety of cancers, it is not advised for prostate cancer that is localized.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!